Pressreleaser | 21 Aug 2023 | Intervacc

Andreas Andersson steps down as President and CEO. Jonas Sohlman has been appointed acting President and CEO for Intervacc

The recruitment of a permanent President and CEO will commence as soon as possible, and, Andreas Andersson will be at the company’s disposal during this transition period. The board recognize and thank him for his work in developing the company to its position today and launching Strangvac into the European market.  

Jonas Sohlman has a solid experience from leading positions in listed companies. Jonas last held the role as CFO at Enorama Pharma. In addition, Jonas has experience in the equine industry and is today the Chairman of the Board of both Flyinge AB as well as for Ridskolan Strömsholm AB. Jonas has also been a professional breeder of show jumping horses.

For more information please contact:

Björn Sjöstrand, Chairman of the board

Phone: +46 727125120
E-mail: bjorn@sjostrands.com

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for immediate publication, through the agency of the contact person set out above on August 21, 2023.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company’s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 – 684 211 10